Oritavancin Activity Tested Against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2016 Mar 23

PMID 27001823

Authors

Rodrigo E Mendes

David J Farrell

Helio S Sader

Robert K Flamm

Ronald N Jones

Affiliations

Soon will be listed here.

Abstract

Oritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.

References

Pournaras S, Ntokou E, Zarkotou O, Ranellou K, Themeli-Digalaki K, Stathopoulos C . Linezolid dependence in Staphylococcus epidermidis bloodstream isolates. Emerg Infect Dis. 2012; 19(1):129-32. PMC: 3557967. DOI: 10.3201/eid1901.111527. View

Deshpande L, Ashcraft D, Kahn H, Pankey G, Jones R, Farrell D . Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2015; 59(10):6256-61. PMC: 4576063. DOI: 10.1128/AAC.01473-15. View

Mendes R, Hogan P, Streit J, Jones R, Flamm R . Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013. Antimicrob Agents Chemother. 2015; 59(4):2454-7. PMC: 4356783. DOI: 10.1128/AAC.04784-14. View

Garcia-Vazquez E, Fernandez-Rufete A, Hernandez-Torres A, Canteras M, Ruiz J, Gomez J . When is coagulase-negative Staphylococcus bacteraemia clinically significant?. Scand J Infect Dis. 2013; 45(9):664-71. DOI: 10.3109/00365548.2013.797599. View

Jarvis W, Jarvis A, Chinn R . National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010. Am J Infect Control. 2012; 40(3):194-200. DOI: 10.1016/j.ajic.2012.02.001. View

Leach K, Swaney S, Colca J, McDonald W, Blinn J, Thomasco L . The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007; 26(3):393-402. DOI: 10.1016/j.molcel.2007.04.005. View

Karavasilis V, Zarkotou O, Panopoulou M, Kachrimanidou M, Themeli-Digalaki K, Stylianakis A . Wide dissemination of linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent ST22 clone. J Antimicrob Chemother. 2015; 70(6):1625-9. DOI: 10.1093/jac/dkv028. View

Zhanel G, Schweizer F, Karlowsky J . Oritavancin: mechanism of action. Clin Infect Dis. 2012; 54 Suppl 3:S214-9. DOI: 10.1093/cid/cir920. View

Flamm R, Mendes R, Hogan P, Ross J, Farrell D, Jones R . In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagn Microbiol Infect Dis. 2015; 81(4):283-9. DOI: 10.1016/j.diagmicrobio.2014.12.009. View

10.

Seral C, Saenz Y, Algarate S, Duran E, Luque P, Torres C . Nosocomial outbreak of methicillin- and linezolid-resistant Staphylococcus epidermidis associated with catheter-related infections in intensive care unit patients. Int J Med Microbiol. 2011; 301(4):354-8. DOI: 10.1016/j.ijmm.2010.11.001. View

11.

Ahlstrand E, Hellmark B, Svensson K, Soderquist B . Long-term molecular epidemiology of Staphylococcus epidermidis blood culture isolates from patients with hematological malignancies. PLoS One. 2014; 9(6):e99045. PMC: 4045895. DOI: 10.1371/journal.pone.0099045. View

12.

Barros M, Branquinho R, Grosso F, Peixe L, Novais C . Linezolid-Resistant Staphylococcus epidermidis, Portugal, 2012. Emerg Infect Dis. 2014; 20(5):903-5. PMC: 4012793. DOI: 10.3201/eid2005.130783. View

13.

Mendes R, Deshpande L, Costello A, Farrell D . Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals. Antimicrob Agents Chemother. 2012; 56(9):4656-61. PMC: 3421855. DOI: 10.1128/AAC.00279-12. View

14.

Munita J, Bayer A, Arias C . Evolving resistance among Gram-positive pathogens. Clin Infect Dis. 2015; 61 Suppl 2:S48-57. PMC: 4551095. DOI: 10.1093/cid/civ523. View

15.

Sanchez Garcia M, De la Torre M, Morales G, Pelaez B, Tolon M, Domingo S . Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010; 303(22):2260-4. DOI: 10.1001/jama.2010.757. View

16.

Tracy L, Furuno J, Harris A, Singer M, Langenberg P, Roghmann M . Staphylococcus aureus infections in US veterans, Maryland, USA, 1999-2008. Emerg Infect Dis. 2011; 17(3):441-8. PMC: 3165993. DOI: 10.3201/eid1703.100502. View

17.

Casey J, Cosgrove S, Stewart W, Pollak J, Schwartz B . A population-based study of the epidemiology and clinical features of methicillin-resistant Staphylococcus aureus infection in Pennsylvania, 2001-2010. Epidemiol Infect. 2012; 141(6):1166-79. PMC: 4360139. DOI: 10.1017/S0950268812001872. View

18.

Peeters M, Sarria J . Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci. 2005; 330(2):102-4. DOI: 10.1097/00000441-200508000-00007. View

19.

Long K, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B . The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother. 2006; 50(7):2500-5. PMC: 1489768. DOI: 10.1128/AAC.00131-06. View

20.

Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z . A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother. 2015; 70(8):2182-90. DOI: 10.1093/jac/dkv116. View